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Abstract
Acne rosacea (AR) is a chronic cutaneous inflammatory disease of the midface. Ocular 
involvement occurs in 30–70% of patients. Although the incidence of this disease is seen 
highest between the ages of 30 and 50 years, it can also develop during childhood. The 
diagnosis depends on clinical findings such as meibomian gland dysfunction (MGD), 
conjunctival hyperemia, and corneal vascularization, and untreated cases can progress 
and lead to vision loss. Pathogenetic factors can be the altered the immune system, colo-
nization of microorganisms, inflammation, abnormalities of sebaceous, and meibomian 
glands, environmental factors, and vascular dysregulation. Differential diagnosis from 
other ophthalmologic and dermatologic diseases is important. Management requires 
an interdisciplinary approach with a step‐wise treatment algorithm. Patients should 
be informed about the chronic course of the disease and avoid the exacerbating fac-
tors. Caring about the lid hygiene and use of non‐preserved artificial eye tears, topical 
ointments including antibiotics, anti‐inflammatory agents are used when necessary. 
However, the mainstay of the therapy is the use of oral antibiotics for a long period. 
Surgical interventions may be needed in cases with a vision‐threatening condition. 
During the long‐term treatment period and disease course, the complications of medica-
tions should also be considered cautiously and patient should be followed up routinely.
Keywords: ocular rosacea, dry eye, meibomian gland, meibomian gland dysfunction, 
treatment
1. Introduction
Acne rosacea (AR) is the chronic inflammatory disease of skin typically involving the cheeks, 
nose, chin, and central forehead. The dermatological findings are transient or persistent ery-
thema, papules, pustules, and telangiectasia. During the chronic course, these findings show 
exacerbations and remissions that may end up with progression. This dermatologic condition 
has been classified by National Rosacea Society into four subtypes based on the clinical fea-
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tures: (1) erythematotelangiectatic rosacea, (2) papulopustular rosacea, (3) phymatous rosacea, 
and (4) ocular rosacea [1]. Flushing, chronic inflammation, and fibrosis are present in dermato-
logic course. The presence of one of the findings: flushing, non‐transient erythema, plaque, dry 
appearance, edema, papules‐pustules, and telangiectasia on the face with burning sensation, 
ocular manifestations, and phymatous changes is indicative of rosacea, and these symptoms 
are graded as mild, moderate, and severe [2]. Ocular manifestations are defined as one of the 
secondary criteria [1].
Under the circumstances of existing acne rosacea, the diagnosis of ocular rosacea (OR) is 
made by the presence of inflammation of the ocular surface, accompanying redness, burn-
ing, and itching symptoms of the eye. The diagnosis is confirmed by the presence of corneal 
infiltration with meibomian gland inflammation, and accompanying skin findings of rosa-
cea [3].
2. Epidemiology
AR is usually seen between ages of 30 and 50 years [4, 5]. The prevalence is reported from 4 to 
22% that is more frequent in fair‐skinned people [5–8]. The OR starts to be detected approxi-
mately 10 years after the diagnosis of AR, with an increasing incidence between ages of 40 
and 50 years [5]. The ocular involvement occurs in 58–72% and interestingly the ocular signs 
may precede in 20% of rosacea patients [9, 10]. Because of mild cutaneous manifestations, the 
ocular findings may be underestimated in children. Therefore, the diagnosis is delayed with 
more ocular complications. In a case series, it was shown that only two of six children with 
ocular rosacea demonstrated cutaneous rosacea findings [11].
Although AR affects women more than men, ocular involvement is to be seen in both sexes 
equally [5, 12]. There is a family history in 15–30% of cases [13, 14]. Hence, with a suspicion 
of family history, the children should be followed up closely and should be kept in mind that 
the condition tends to progress in adulthood [15].
3. Pathogenesis
Although AR has no proven cause, scientific studies showed that there is dysregulation of 
vascular, immunologic, and nervous systems [16, 17]. Ocular surface is the mainly affected 
area with OR. Ocular surface compromises cellular components of the palpebral and bulbar 
conjunctiva such as corneoscleral limbus, cornea, eyelid margins, eyelashes, and tear film [18].
3.1. Altered immune system
Altered immune system may be one of the factors. It was postulated that a type IV hyper-
sensitivity reaction may be responsible for the conjunctival inflammation in OR in which the 
reactant is unknown [19, 20].
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3.2. Colonization of microorganism
Demodex folliculorum is a saprophytic mite that is found in normal flora of the skin. There are 
studies demonstrating that the Demodex density increased in rosacea patients [21, 22].
Bacillus olenorium serum immunoreactivity was detected in ocular rosacea patients. Its pro-
teins cause high immune reactions [22, 23].
Staphylococcus epidermidis and Propionibacterium acnes that are found commonly in lid flora are 
accused microorganisms for their production of high levels of bacterial lipases [24].
In a study, Chlamydia pneumoniae antigen was detected in 40% of skin biopsies patient with 
rosacea [25].
Moreover, Helicobacter pylori IgG antibodies were found in 81% of the acne rosacea patients 
with dyspepsia, but there is a debate whether this is a coincidence or not [26]. The proteins 
produced by these pathogens might be responsible for the some aspects of rosacea.
The increased amount of free fatty acids produced by meibomian glands causes tear film 
instability and irritates the ocular tissues [27]. This increase may be due to biochemical abnor-
mality of the meibomian gland secretions or lipolytic exoenzymes of bacteria which degrade 
lipids into free fatty acids [28].
3.3. Inflammation
OR was found to be associated with the increased tear fluid levels of several inflammatory 
mediators such as interleukin‐1 (IL‐1) and gelatinase B activity [29]. Matrix metalloprotein-
ases (MMP), interferon‐alpha (IFN‐α), and inflammatory cytokines seem to be an important 
component of pathophysiology [30].
The meibomian glands of rosacea patients cause keratinization of epithelial cells, end up with 
thickening of secretions, plugging of the orifices, and trapping of the secretions [31].
3.4. Environmental factors
Many rosacea patients are aware of some factors that exacerbate their symptoms. Although 
these triggering factors differ for each patient: alcohol, sunlight, wind, temperature extremes, 
hot, and spicy foods, vigorous exercise, hot baths, medications that dilate blood vessels, 
menopause, and emotional factors (stress, anger, and embarrassment) can also play role in 
the pathogenesis [32–34].
3.5. Genetics
Rosacea is associated with familial predisposition [35]. In a study conducted in twin pairs, 
rosacea contribution has been reported equally by genetic and environmental factors [36]. The 
genetic predisposition showed single nucleotide polymorphisms in HLA‐DRA and BTNL2 




3.6. Vascular dysregulation and neurologic system
There is vascular dilatation and telangiectatic vessels and increased blood flow, causing ery-
thema, flushing, and neovascularization [5, 34, 38], which is probably under control of the 
sympathetic system [39].
4. Diagnosis
The diagnosis of both dermatological rosacea and ocular rosacea is clinical. There is no single‐
specific test—even skin biopsy—to confirm the diagnosis.
Ocular involvement is varied and non‐specific. Most of the patients refer to ophthalmologist 
with dry eye symptoms (Table 1). No correlation exists between the severity of the ocular 
manifestations and that of the skin lesions. However, in patients with increased flushing, 
ocular rosacea prevalence is higher [40].
Although rosacea is uncommon in pediatric cases, it deserves attention due to undiagnosed 
ocular rosacea that is common with severe ocular complication [41]. History of triggering fac-
tors should be investigated and dermatologist consultation is required.
4.1. Clinical feature
Both eyes are usually affected simultaneously, but unilateral or sequential involvements can 
also occur.
The primary and the starter of the ocular involvement is the meibomian gland dysfunction 
(MGD) [42]. Ghanem et al. reported that the most common ocular signs in patients with rosa-
cea from the ophthalmologic clinic were meibomian gland dysfunction (MGD) in 85.2%, lid 
margin telangiectasias in 53.4%, blepharitis in 44.3%, and interpalpebral hyperemia in 40.9%. 
Accordingly, patients from the dermatology clinic were reported to exhibit MGD in 27.3%, 
chalazion/hordeolum, lid margin telangiectasia in 18.2%, anterior blepharitis in 13.6%, and 
pinguecula in 13.6% [9] Vision loss is a rare but devastating complication [43]. OR has been 
graded as mild, moderate, and severe (Table 2) [2].
Ocular symptoms




 – sensitivity to light (photophobia)
 – tearing
 – red and swollen eyelids
 – blurry or decreased vision
Table 1. Ocular symptoms of the ocular rosacea patient.
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4.2. Symptoms
Feeling of dryness, irritation symptoms with burning and stinging and feeling of having for-
eign body sensation in the eye are common. Blurry vision, redness, sensitivity to light (photo-
phobia), tearing, itching, red, and swollen eyelids are the other encountered symptoms.
4.3. Signs
It is not rare that the symptoms of the patient are not proportional with the ocular findings. 
Reduced fluorescein tear breakup time, punctate staining on the cornea, and bulbar con-
junctiva (Figure 1). Superficial punctate keratopathy (due to tear film instability), dry eye 
disease, blepharitis, styes, MGD, eyelid inflammation‐collaretes, telangiectasis, conjunctival 
hyperemia, conjunctival scarring, punctate epithelial keratitis, corneal infiltrate/vascular-
ization, corneal thinning, corneal astigmatism, corneal ulceration, phlyctenules, phlycte-
nular keratitis, limbal pannus, episcleritis, scleritis, corneal melting, and perforation, iritis, 
periorbital edema, recurrent chalazia, pannus, neovascularization, trichiasis (Figures 1–5) 
[43–46].
4.3.1. Eyelid
The lipid layer produced by meibomian glands stabilizes the tear film and prevents evapora-
tion. Abnormality of this function is the primary cause of the blepharitis and evaporative‐type 
dry eye. Dry eye can be detected by decreased tear breakup times. There is inflammation, 
dilatation, and occlusion of the meibomian glands [31]. With pressure to eyelid margins, there 
is hardness to express the secretion, and usually occluded by toothpaste‐like material namely 
meibomana. Hordeolum and chalazion are the signs of focal inflamed obstructive MGD. 
In chronic course, there will be telangiectatic vessels around the orifices of the meibomian 
glands. At the end, the ducts are fully keratinized and disappears leading the meibomian 
gland dropout.
Grade Involved areas Signs and symptoms Recommended treatment
Mild Eyelid margin, 
meibomian gland
Mild itching and dry eye sensation
Fine scaling and erythema of eyelid margins
Mild conjunctival hyperemia
Topical treatment only
Moderate Ocular surface Moderate burning, tearing, foreign body sensation
Eyelid margin irregularities, erythema and 
telangiectasia
Prominent conjunctival hyperemia, ciliary injection
Hordeolum and chalazion formation
Topical, systemic treatment
Severe Corneal involvement 
and decreased vision
Pain, sensitivity to light, blurred vision
Severe conjunctival inflammation, madarosis 
and trichiasis
Corneal involvement
Topical, systemic, surgical 
treatment





Conjunctival hyperemia is the common finding. Hyperemia is mostly obvious in interpalpe-
bral area. In 9% of OR, there is also conjunctival scarring [47].
4.3.3. cornea
Disease starts with inferior punctate epitheliopathy. Superficial vascularization of the periph-
eral cornea (especially triangular in shape and extending from inferior cornea) develops in 
Figure 2. Ocular rosacea with sterile corneal infiltrate, lid telangiectasia, meibomian gland occlusion and foamy secretion.
Figure 1. Ocular rosacea patient with irregular ocular margin, conjunctival hyperemia and trichiasis.
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untreated cases. In case of recurrent epithelium defects, one should be suspicious of OR also. 
Inflammatory episodes will end up with devastating problems, such as corneal scarring, thin-
ning even perforation and sight threatening keratitis [48–51].
4.4. Ocular tests and imaging
Tests of evaporative dry eye are altered in OR. Tear osmolarity values, Ocular surface dis-
ease index (OSDI) questionnaire and corneal staining scores were significantly higher, and 
Figure 3. Bulbar interpalpebral conjunctival hyperemia with fine corneal vascularization.




Schirmer‐I test and fluorescein tear breakup time were significantly lower, which all confirms 
tear hyperosmolarity and tear film dysfunction [52].
Dry eye in rosacea patients can also be diagnosed by tear meniscus measurement with opti-
cal coherence tomography (OCT) with considerable sensitivity and specificity [53]. Central 
corneal thickness, corneal hysteresis and corneal resistance factors were all significantly 
decreased in OR patients when compared to healthy controls [54]. Patients with OR show 
significant meibomian gland dropout which can be demonstrated by meibography (Figure 6) 
Figure 6. Ocular rosacea. Meibography, meibomian dropout.
Figure 5. Corneal haze inferotemporally signifying healed corneal involvement of ocular rosacea.
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[31, 42]. In vivo confocal microscopy findings revealed inflammatory changes of ocular surface 
and even Demodex infestations on eyelids [55, 56].
5. Differential diagnosis
5.1. From dermatological diseases
In patients with suspicion of OR, if facial dermatologic inflammatory changes exist, clinician 
would be aware of three main differential diagnosis [57]. These are as follows:
Acne vulgaris: The presence of comedones—which does not exist in rosacea—in young 
patients direct the clinician to diagnosis of acne vulgaris.
Seborrheic dermatitis: In seborrheic dermatitis, facial erythema is accompanied by yellowish 
scaling and prominent dandruff.
Perioral dermatitis: There is perioral involvement without flushing or telangiectasia.
5.2. From ophthalmological diseases
Ocular findings must be differentiated from the other causes of dry eye.
Corneal involvements must be differentiated from herpetic or bacterial keratitis and recurrent 
epithelial defects [48, 58, 59].
All forms of conjunctivitis are in differential diagnosis. Due to chronic course and leading to 
conjunctival scarring, chlamydial conjunctivitis deserves attention.
In severe OR, which ends up with inferior thinning and irregular astigmatism, it may resem-
ble to keratoconus [51].
6. Management
For an effective therapeutic strategy, an interdisciplinary collaboration is needed between 
ophthalmologist and dermatologist. The stepwise approach is recommended.
 ⁻ Inform patient about the chronic nature of their disease and requirement for regular 
follow‐up.
 ⁻ Avoid triggering and exacerbating factors. It might be advised to keep a daily diary to 
figure out triggering factors.
 ⁻ Avoid wearing contact lenses and eye makeup when the symptoms are exaggerated.
 ⁻ Lid hygiene: Hot compressing and MG expressions by mechanical massage to lids, lid 
hygiene cleaning solutions, eyelid scrubs massage to the tarsal plate [60]. This is the main 




 ⁻ Lubricants: Lubricants are used to decrease inflammatory mediators, and to provide 
symptomatic relief. Non‐preserved artificial tears are recommended with a patient‐ 
individualized dosage [61]. The initial high dosages might be tapered gradually. OR is 
usually mild and responds well to lid hygiene and lubricants, but must be advised to do 
regularly to avoid exacerbations of symptoms.
 ⁻ Topical antibiotics: Azithromycin 1.5% eye drops are effective for MGD treatment even 
with phlyctenular keratoconjunctivitis complicating OR [62, 63]. It has an anti‐inflamma-
tory effect as well as an antimicrobial effect. Topical antibiotic ointments (fucidic acid and 
metronidazole gel applied to lid margins), especially in the nighttime, are also effective to 
restore the flora.
 ⁻ Mainstay of the treatment is the use of systemic antibiotics. Due to relapses, maintenance 
treatment may be 6 months. Low doses with longer duration of the antibiotic usage must 
be preferred to benefit from the anti‐inflammatory effect without inducing resistance and 
other side effects.
 ◦ Systemic tetracycline/doxycycline/minocycline shows the therapeutic effects by decreas-
ing lid flora, inhibiting collagenase activity which prevents corneal thinning, inhibiting 
inflammatory mediators (i.e. MMP), decreasing concentration of free fatty acids [64–66].
 ◦ Clarithromycin are also effective to H. pylori [67].
 ◦ Metronidazole has anti‐inflammatory, anti‐microbic, anti‐parasitic, and immunosup-
pressive effects [68].
 ◦ Azithromycin 3 times per week for 4 weeks [69].
 ◦ Erythromycin is appropriate for children <8 years old to avoid the untoward effects of 
tetracycline [70].
 ⁻ Topical anti‐inflammatory agents: Topical corticosteroids suppress the exacerbation epi-
sodes and are effective in prevention of the recurrent corneal erosions when used in com-
bination with systemic doxycycline [71]. The application would be tapered and stopped 
after the symptomatic relief. Topical steroids should be used cautiously, minimal dose 
with minimal duration, under the supervision of the ophthalmologist. Instead of steroids, 
topical cyclosporine (with 0.05% concentration) might be the choice for a longer period of 
treatment [72].
 ⁻ Dietary intervention with omega‐3 fatty acids for 6 months is effective in decreasing the 
dry eye symptoms and signs in ocular rosacea [73].
 ⁻ Surgical: Intraductal meibomian gland probing is shown to be a promising technique to 
improve dry eye symptoms related with OR [74]. Epilation of trichiatic lashes will elimi-
nate the mechanical insult to ocular surface.
In cases of severe corneal involvement, surgical options are indicated [49]. Progressive epi-
theliopathy unresponsive to topical treatment with hazy epithelium extending centrally, 
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indicating limbal stem cell insufficiency, is treated with limbal stem cell transplantation [75]. 
Thinning of the cornea and threatening perforation are treated with conjunctival flaps or 
amniotic membranes [43]. Little corneal perforations may benefit from cyanoacrylate glues. 
Minority people with untreated or resistant to treatment may need keratoplasty at the end of 
long‐term OR [49].
Rosacea naturally waxes and wanes. However, because the damage from rosacea can be 
progressive, the long‐lasting use of therapy has advantages. Due to the lack of prospective 
controlled studies, the optimum modality and duration for treatment and prevention of OR 
recurrence remain unclear. The duration of the treatment depends on the ophthalmologist's 
decision and the severity of the ocular involvement. There is a consensus to give treatment for 
several months, and tapering the doses within follow‐ups.
7. Complications
Long‐standing OR will end up with irregular eyelid margins and misdirected eyelashes (tri-
chiasis). Untreated corneal involvement will lead to vision loss.
The long‐term use of topical steroids may cause increased intraocular pressure, cataract for-
mation, corneal thinning, and exacerbation of underlying herpes. Chronic use of systemic 
antibiotics makes necessary to control the hepatic functions.
Although it is recommended to use low dose with a long duration, clinician should be cau-
tious about the potential side effects of oral tetracycline as gastrointestinal discomfort, vaginal 
yeast infections, photosensitivity, and decreased effectiveness of oral contraceptives. It is not 
appropriate for the children <8 years old, because of its accumulation in bone, color changes 
in teeth, and interfering enamel development [76].
Oral isotretinoin, which has both anti‐inflammatory and immunomodulatory properties, has 
been used as a treatment for severe rosacea, particularly phymatous presentation by derma-
tologists [77]. In these cases, routine ophthalmologic follow‐up should be recommended since 
the retinoids may cause blepharoconjunctivitis, worsening telangiectasias and may lead to 
severe keratitis [78].
8. Conclusion
Rosacea, mainly being a dermatological disease, may show ocular manifestations that some-
times may have severe consequences. The diagnosis mainly depends on the clinical findings 
and suspicion of the clinician. The evaluation and management should be performed by a 
collaborative approach by both dermatologist and ophthalmologist. The management should 
have a stepwise structure. The complications of both the disease and the treatment should be 
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